RxDoctor Payments Data

Zakir Sahul, MD

Interventional Cardiology · Ypsilanti, MINPI 1083659486

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 16 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by Kestra Medical Technology Services, Inc. at 41.7% of the total. That places this record below the midpoint for interventional cardiology clinicians in MI, where the typical reported total is $6,857.

$412in general payments, 2019–2025

Across 16 payments — averaging $25.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Kestra Medical Technology Services, Inc.$172
  • Edwards Lifesciences$65
  • Medtronic$44
  • Cordis US CORP.$39
  • Cardiovascular Systems Inc.$36
  • Abbott$31
  • plus $24 from 1 others
$274,862in research payments, 2019–2025

Across 38 payments — averaging $7233.21 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$185K
  • Abbott$90K

What the payments were for

  • Food & beverage$412100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$412 in reported general payments places this provider in the 0th percentile of 187 interventional cardiology providers in Michigan.

See all interventional cardiology providers in Michigan

Medicare billing

Part B allowed, 2024
$147,823
Medicare patients
1,333
Services billed
1,955

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban130$154,819
Repatha SureclickEvolocumab34$34,388
XareltoRivaroxaban16$24,251
Icosapent Ethyl11$3,041
Atorvastatin Calcium160$2,912
Metoprolol Succinate151$2,833
Diltiazem 24hr Er (Cd)Diltiazem Hcl57$2,191
Isosorbide Mononitrate ErIsosorbide Mononitrate85$2,114
Metoprolol Tartrate120$1,073
Bumetanide14$1,010
Rosuvastatin Calcium54$978
Ezetimibe43$813
Nitroglycerin55$742
Losartan Potassium64$733
Carvedilol44$699

Paid to pharmacies, not to this prescriber.

Other interventional cardiology in Ypsilanti

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →